Mesoblast Limited Seeks ASX Quotation for 1.9 Million Shares Issued via Employee Option Exercise

Employee Share Option Plan Facilitates Recent Share Issuance

Mesoblast Limited has submitted an application to the Australian Securities Exchange for the quotation of 1,885,334 fully paid ordinary shares issued on 16 July 2026. These shares were transferred to an employee share plan trustee to enable the exercise of options granted under the company’s employee share option plan, which had met all vesting requirements. This issuance continues Mesoblast's strategy of using equity-based incentives to align employee and shareholder interests.

The announcement did not specify the cash consideration per share; however, the shares were issued to the trustee at nil cash consideration, with the exercise funded through satisfaction of vesting milestones tied to the original option grants. This approach is typical for equity incentive programs where employees exercise options granted as performance-based benefits. The newly issued shares rank equally with existing ordinary shares from the date of issue, ensuring consistent voting and dividend rights.

Mesoblast’s Capital Structure After New Share Quotation

Following the quotation of these shares, Mesoblast’s total quoted ordinary share capital will be 1,298,748,110 fully paid shares listed under the ticker MSB on the ASX. This figure represents the publicly traded equity available for investor transactions, reflecting Mesoblast’s status as a significant listed entity with a substantial public float.

In addition to quoted shares, Mesoblast holds 90,901,277 unquoted options with varying expiry dates and exercise prices, alongside 19,912,165 unquoted warrants across four series: MSBAO, MSBAP, MSBAA, and MSBAB. These unquoted securities are contingent instruments that may convert into shares in the future, subject to their specific terms. The sizable option and warrant holdings highlight Mesoblast’s active capital management and employee incentive strategies.

Employee Incentive Plan and Shareholder Approval Details

The employee share option plan governing this issuance is detailed in Item 9 of the Notice of Meeting released on 27 October 2025, which outlines the scheme’s terms as approved by shareholders. Such plans are critical for attracting and retaining talent by providing equity-linked compensation, aligning employee goals with long-term shareholder value, and rewarding performance without immediate cash payouts. Mesoblast’s plan explicitly allows share issuance upon exercise of vested options by employees.

This issuance qualifies for exemption under ASX Listing Rule 7.2 exception 13, meaning no further shareholder approval was required. This exception applies to securities issued under previously shareholder-approved employee schemes, streamlining the process for routine option exercises. Mesoblast’s reliance on this exemption reflects its adherence to an established employee share option framework.

Mechanics of Option Exercise and Trustee Role

The 1,885,334 shares were transferred to an employee share plan trustee, which holds shares on behalf of participating employees. This trustee arrangement is common in employee share schemes to maintain administrative separation between employee holdings and company treasury shares. The trustee is the registered shareholder, while employees hold beneficial interests documented separately.

The share issuance reduced the company's total unquoted options as vested options were exercised and converted into shares. A contemporaneous notification regarding unquoted securities was filed, detailing this reduction. The simultaneous filing of the quotation application and unquoted securities notification provides transparency on the capital structure changes resulting from this equity exercise.

Nil Cash Consideration and Vesting Condition Fulfillment

The shares were issued to the trustee at nil cash consideration, reflecting that the options were granted as performance-linked compensation. Vesting conditions—such as continued employment or achievement of milestones—had to be met before these options could be exercised. With vesting satisfied, the options were exercised without additional cash inflows to the company.

This nil consideration issuance is economically equivalent to granting shares as an incentive reward. The value was effectively provided at the original option grant stage, contingent on vesting. Accounting treatment typically records the issuance at the fair value on the exercise date, representing the economic benefit transferred to employees.

Regulatory Compliance and Investor Transparency

Mesoblast lodged an Appendix 2A with the ASX, the standard form for notifying new securities quotation. This form discloses details such as security type, quantity, issue date, consideration basis, and resulting capital structure, ensuring compliance with ASX Listing Rules. The filing informs the market of capital structure changes and enables proper trading code assignment.

Disclosure of the employee share option plan terms via the Notice of Meeting demonstrates compliance with ASX Listing Rules and the Corporations Act 2001 (Cth). Shareholder approval of such schemes is a governance prerequisite before equity issuance. Public availability of these terms enables investors to evaluate the design and dilution impact of Mesoblast’s equity compensation framework.

Unquoted Securities and Potential Future Dilution

Mesoblast’s unquoted securities portfolio represents significant potential dilution. The company holds 90,901,277 unquoted options and 19,912,165 unquoted warrants, with the largest warrant series (MSBAO) comprising 15,027,327 instruments. Warrants function as equity derivatives granting rights to subscribe for shares at set prices, typically over longer durations than options.

This extensive unquoted portfolio reflects Mesoblast’s ongoing capital raising and employee incentive efforts. Options are commonly issued to employees and management as retention and performance rewards, while warrants may have been granted to investors or partners as financing incentives. If exercised, these instruments could substantially increase the company’s issued share capital beyond the current 1.3 billion quoted shares, a key consideration for investors regarding earnings per share dilution and voting power.

Industry Context and Equity Incentives in Biotechnology

Operating in the regenerative medicine and cell therapy sector, Mesoblast faces intense competition for specialized talent, making equity compensation vital for recruitment and retention. Biotechnology companies often rely heavily on equity incentive plans due to long development cycles and high business risk, enabling cash conservation while offering employees upside participation.

The issuance of approximately 1.9 million shares through this option exercise represents about 0.15% dilution relative to Mesoblast’s total quoted shares, indicating a measured approach to equity grants that balance incentive impact with shareholder dilution. However, cumulative option exercises over time may have more significant effects, underscoring the importance for investors to monitor ongoing disclosures related to unquoted options and warrant exercises.